Market Research Logo

Primary Sclerosing Cholangitis Market - Size, Share, Trends, and Forecast to 2023

Primary Sclerosing Cholangitis Market - Size, Share, Trends, and Forecast to 2023

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.
Market Dynamics
Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.
However, failure of drug candidates to provide desired study outcomes and the withdrawal of late phase clinical trials of potential drug molecules are factors hindering the market growth.
Key features of the study:

This report provides in-depth analysis of primary sclerosing cholangitis market and provides pipeline analysis for the same
It elucidates potential opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global primary sclerosing cholangitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the primary sclerosing cholangitis market

Detailed Segmentation:

Global Primary Sclerosing Cholangitis Market, By Drug:

BTT1023
GS-9674
NGM282
OCA
Cenicriviroc
LUM001
DUR928
norUDCA
HTD1801
IDN-7314
STP705

Global Primary Sclerosing Cholangitis Market, By Region:

North America

Regional Overview

Latin America

Regional Overview

Europe

Regional Overview

Asia Pacific

Regional Overview

Middle East

Regional Overview

Africa

Regional Overview

Company Profiles

Acorda Therapeutics, Inc.*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.

“*” marked represents similar segmentation in other categories in the respective section.


Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Overview
Optimistic, Likely and Pessimistic Overview
Market Dynamics, Pipeline, and PEST Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
PEST Analysis
Pipeline Analysis
Initiatives Focusing On PSC Support And Research
Reason For Phase 3 Drug Withdrawal
Challenges Faced by Orphan Drug Candidates
Epidemiology
Global Primary Sclerosing Cholangitis Market, By Drug
Introduction
BTT1023
Research Details
GS-9674
Research Details
NGM282
Research Details
OCA
Research Details
Cenicriviroc
Research Details
LUM001
Research Details
DUR928
Research Details
norUDCA
Research Details
HTD1801
Research Details
IDN-7314
Research Details
STP705
Research Details
Global Primary Sclerosing Cholangitis Market, By Region
Introduction
North America
Regional Overview
Latin America
Regional Overview
Europe
Regional Overview
Asia Pacific
Regional Overview
Middle East
Regional Overview
Africa
Regional Overview
Competitive Landscape
Company Profiles
Acorda Therapeutics, Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Gilead Sciences, Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
NGM Biopharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Intercept Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Dr. Falk Pharma GmbH
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Allergan Plc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Shire Plc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Durect Corporation
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Conatus Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Sirnaomics, Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Shenzhen HighTide Biopharmaceutical Ltd.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Analyst Views
Section
References
Research Methodology
About us and Sales Contact

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report